X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The funding will support CancerVax to focus on the development of a discovery-stage product for single-disease cancer treatments targeting Ewing sarcoma, a rare but deadly bone and soft tissue cancer primarily affecting children and young adults.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Vaccine
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 03, 2024
Details:
Universal CAR-T Cell Platform – A novel and customizable low-cost treatment, to be delivered as a shot, that can reprogram natural immune T-cells inside the body to seek and destroy targeted cancer cells.
Lead Product(s): CAR-T Cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2023
Details:
The net proceeds from the offering will be used to fund the further development of novel cancer vaccines leveraging the body’s immune system to destroy cancer cells.
Lead Product(s): Cancer Vaccine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Vaccine
Partner/Sponsor/Collaborator: StartEngine
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 14, 2023
Details:
CAR-T cells and bispecific antibodies targeting this protein biomarker. The findings of this work will create and evaluate new promising tools for recruiting and activating the patient’s own immune system to track and destroy Ewing sarcoma tumors.
Lead Product(s): Antibody,CAR T Cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: UCLA
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2023
Details:
A non-provisional patent application has been filed to protect its invention which leverages cutting-edge bioengineering techniques such as CRISPR and mRNA to develop a breakthrough universal cancer vaccine, that will use the body’s immune system to fight cancer.
Lead Product(s): mRNA-based Vaccine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
